FcRn normally rescues IgG antibodies from intracellular destruction and returns them to circulation. Blocking that recycling pathway accelerates IgG clearance, including pathogenic autoantibodies, without directly eliminating the B cells that produced them.
Johnson & Johnson has secured FDA approval for IMAAVY in warm autoimmune hemolytic anemia, giving eligible patients aged 12 and older the first treatment specifically approved in the United States for wAIHA.
Discover what Johnson & Johnson’s new IMAAVY data mean for earlier gMG treatment, sustained control, safety and FcRn competition.
The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.
Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.